Literature DB >> 7781200

Single dose kinetics of piperacillin during continuous arteriovenous hemodialysis in intensive care patients.

E Keller1, J Böhler, A Busse-Grawitz, P Reetze-Bonorden, B Krumme, P Schollmeyer.   

Abstract

Piperacillin (Pi) kinetics in patients with acute renal failure treated by continuous arteriovenous hemodialysis (CAVHD) are not known. Therefore, dosing regimens have been based on kinetic data derived from patients with chronic renal failure and principal pharmacokinetic considerations [Reetze-Bonorden et al. 1993]. From these estimations it has been predicted that approximately 30% of the dose of Pi is removed by CAVHD (dialysate/ultrafiltrate (D/UF) flow rate 1.5 liter/hour). To confirm this estimate single dose (4g i.v.) Pi kinetics were studied in 12 intensive care patients with anuric acute renal failure due to septicemia treated by CAVHD. Pi plasma and D/UF levels were measured by HPLC. Sieving/Saturation of Pi in the D/UF was 0.71 +/- 0.21 (+/- SD). With a mean D/UF flow rate of 20.4 +/- 1.5 ml/min, the mean extracorporal clearance (Clextra) was 12.2 +/- 1.0 ml/min and accounted for 29% (range 14-48%) of total body clearance (ClB = 47.1 +/- 22.3 ml/min). In 7 out of 12 patients the fraction of the dose eliminated by CAVHD reached a significant value above 25%. The mean volume of distribution (Vd) and elimination half life (t1/2) were 25.8 +/- 3.8 liter and 7.4 +/- 2.9 hours, respectively. In conclusion the extent of extracorporal elimination of Pi by CAVHD was well in agreement with the estimation previously published. In intensive care patients with acute renal failure on continuous hemodialysis Pi dosing should take into account the possibly significant elimination of Pi. The usual dose for anuric patients may be increased by 50% to avoid underdosing in these critically ill patients.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7781200

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  5 in total

1.  Pharmacokinetics of piperacillin-tazobactam in anuric intensive care patients during continuous venovenous hemodialysis.

Authors:  Silke C Mueller; Jolanta Majcher-Peszynska; Heiko Hickstein; Astrid Francke; Annette Pertschy; Martin Schulz; Ralf Mundkowski; Bernd Drewelow
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

Review 2.  Pharmacokinetics of drugs used in critically ill adults.

Authors:  B M Power; A M Forbes; P V van Heerden; K F Ilett
Journal:  Clin Pharmacokinet       Date:  1998-01       Impact factor: 6.447

Review 3.  Drug dosing during intermittent hemodialysis and continuous renal replacement therapy : special considerations in pediatric patients.

Authors:  Michael A Veltri; Alicia M Neu; Barbara A Fivush; Rulan S Parekh; Susan L Furth
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

Review 4.  Beta-lactam dosing in critically ill patients with septic shock and continuous renal replacement therapy.

Authors:  Marta Ulldemolins; Sergi Vaquer; Mireia Llauradó-Serra; Caridad Pontes; Gonzalo Calvo; Dolors Soy; Ignacio Martín-Loeches
Journal:  Crit Care       Date:  2014-06-23       Impact factor: 9.097

5.  Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review.

Authors:  Fekade Bruck Sime; Michael S Roberts; Sandra L Peake; Jeffrey Lipman; Jason A Roberts
Journal:  Ann Intensive Care       Date:  2012-07-28       Impact factor: 6.925

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.